DERMATOLOGIC CLINICS is a leading journal in the field of dermatology, published by W B SAUNDERS CO-ELSEVIER INC. Since its inception in 1983, the journal has consistently provided a platform for the dissemination of high-quality research and clinical insights, earning its place in the prestigious Q1 quartile for dermatology in 2023. With a Scopus ranking of #34 out of 142 in its category and a commendable 76th percentile, DERMATOLOGIC CLINICS remains essential reading for clinicians, researchers, and students alike. The journal features comprehensive reviews and original articles that address the latest advancements and challenges in dermatologic diagnostics and treatments. Though it does not offer Open Access, it is widely accessible ensuring a broad readership. With a commitment to advancing the understanding of skin disorders, DERMATOLOGIC CLINICS continues to uphold its legacy of excellence in dermatological scholarship.

Journal of Drugs in Dermatology, an esteemed publication in the field of dermatology, serves as a vital resource for researchers, clinicians, and healthcare professionals dedicated to advancing knowledge and practices in skin-related therapies and treatments. Established in 2002 and published in the United States, this journal focuses on a wide range of topics pertinent to dermatological pharmacology and therapeutics, reflecting contemporary scientific advancements and innovative approaches to patient care. With a strong presence in Scopus rankings, situating it at rank #73 within the dermatology category, and achieving a commendable Q2 quartile classification in both dermatology and general medicine categories, the journal is committed to enhancing understanding of drug efficacy and safety in dermatological conditions. While the journal maintains a traditional access model, its impact factor underscores its significance in the research community, supporting the ongoing dialogue between academia and clinical practice. We invite professionals and students alike to explore the latest findings and contribute to the progressive discourse on dermatological treatments through this important publication.

Reumatologia Clinica is a distinguished journal dedicated to the field of Rheumatology, published by Elsevier España SLU. With its ISSN of 1699-258X and E-ISSN 1885-1398, the journal aims to disseminate pivotal research findings and clinical studies from 2005 to 2024, spotlighting advancements in the understanding and treatment of rheumatic diseases. Based in Barcelona, Spain, it plays a vital role in the academic community, ranking in the Q3 category for Rheumatology as of 2023, with a Scopus ranking of #44 out of 73, placing it in the 40th percentile. Although it operates under a traditional access model, the journal is committed to academic excellence, providing researchers, healthcare professionals, and students with invaluable insights that drive the field forward. Reumatologia Clinica serves as an essential resource for those looking to deepen their knowledge and contribute to the evolving landscape of rheumatologic research.

Dermatologic Therapy is a leading peer-reviewed journal published by WILEY-HINDAWI that focuses on the multifaceted field of dermatology. Established in 1996 and continuing its profound impact into 2024, the journal has earned an impressive Q1 rating in Dermatology and ranks 11th out of 142 in the Scopus categorization, placing it in the 92nd percentile. With its headquarters in the United Kingdom, the journal's mission is to advance the understanding and treatment of skin diseases through the dissemination of high-quality research, reviews, and clinical information. Although not an open-access journal, it provides extensive access options to ensure that vital research reaches its audience. By leading scholarly discourse and innovation in dermatological treatments, Dermatologic Therapy serves as an essential resource for researchers, clinicians, and students dedicated to improving skin health worldwide.

Dermatologie, published by SPRINGER HEIDELBERG, is a prominent journal dedicated to the advancing field of dermatology. With its ISSN 2731-7005 and E-ISSN 2731-7013, this journal has established itself as a valuable resource for researchers, professionals, and students alike. Originating in Germany, the journal focuses on disseminating innovative research from 2022 to 2024, contributing significantly to the understanding of skin health and disease management. Despite its current ranking within the Q3 category in dermatology and a Scopus rank of #88/142, it provides critical insights and advances in clinical practice, epidemiology, and therapeutic modalities. With an emphasis on open discourse, it seeks to foster collaboration among healthcare professionals and researchers, thereby enhancing the quality and accessibility of dermatological research. Engage with Dermatologie to stay at the forefront of the latest advancements in skin-related health issues.

Modern Rheumatology is a premier journal dedicated to advancing the field of rheumatology through high-quality peer-reviewed research. Published by Oxford University Press, this journal reflects the latest developments in rheumatologic medicine, catering to researchers, clinicians, and students alike. With an H-Index highlighting its scholarly impact, Modern Rheumatology occupies a notable position, ranking Q2 in both the fields of Medicine and Rheumatology in 2023, and is listed among the top 25 journals in its category by Scopus. Spanning from the year 2000 to 2024, the journal features a diverse array of topics aimed at addressing current challenges and innovations in the field. Although it does not offer Open Access, it provides essential insights for professionals seeking to stay abreast of evolving treatment modalities and research breakthroughs. Located in the heart of the United Kingdom, Modern Rheumatology is a vital resource for anyone committed to enhancing the understanding and treatment of rheumatic diseases.

Actas Dermo-Sifiliograficas, published by Elsevier España, stands as a pivotal resource in the realms of dermatology, histology, and pathology and forensic medicine. With its ISSN of 0001-7310 and E-ISSN 1578-2190, this esteemed journal has transitioned to an Open Access model since 2020, facilitating broader dissemination of impactful research. Operating from its Madrid headquarters, it has been a vital platform for scholarly exchange since its inception in 1945, continuing through its converged years until 2024. The journal holds a Q3 ranking in dermatology, histology, and pathology and forensic medicine as of 2023, reflecting its relevance in the academic community where it ranks 79th in dermatology and 126th in pathology among its peers. With a commitment to advancing knowledge and practice in its fields, Actas Dermo-Sifiliograficas serves as an essential repository for researchers, professionals, and students seeking to engage with the latest findings and innovative perspectives in skin and disease research.

The Journal of Cutaneous Immunology and Allergy, published by FRONTIERS MEDIA SA in Switzerland, is an esteemed Open Access platform dedicated to advancing research in the intersecting fields of dermatology, immunology, and allergy. Since its inception in 2018, this journal has provided a vital resource for the dissemination of innovative research findings and critical reviews, enhancing our understanding of cutaneous conditions related to immune responses. Although currently classified in the Q4 quartile in both Dermatology and Immunology & Allergy categories as of 2023, the journal continues to strive for recognition within the scientific community, encouraging collaboration and knowledge sharing among researchers, clinicians, and experts. The journal boasts an E-ISSN of 2574-4593 and is committed to making high-quality research freely accessible to all, thus fostering greater insights into the complexities of skin-related immune disorders. Join us in this journey to explore the forefront of cutaneous research and contribute to the evolving dialogue in this dynamic field.

The INTERNATIONAL JOURNAL OF DERMATOLOGY, published by WILEY, stands as a premier scholarly platform in the field of dermatology, with a notable impact factor that affirms its quality and renown. Established in 1963 and converging through to 2024, this journal is recognized as a Q1 category publication, ranking in the top 20% of journals within the dermatology field according to the Scopus ranking system, where it occupies the 28th position among 142 journals. This reflects its dedication to advancing the understanding and treatment of skin diseases, making it a vital resource for researchers, healthcare professionals, and medical students alike. Although it does not provide open access options, articles published in this journal cover a broad range of dermatological topics, ensuring that it serves as a comprehensive and authoritative source for cutting-edge research and clinical practices. With its rigorous peer-review process and commitment to high standards, the INTERNATIONAL JOURNAL OF DERMATOLOGY remains indispensable for those engaged in dermatological science and practice.

The Journal of Dermatology, published by Wiley, is a premier academic journal dedicated to advancing the field of dermatology, with its esteemed reputation reflected in its Q1 ranking in Dermatology and a remarkable Q2 ranking in Miscellaneous Medicine as of 2023. Since its inception in 1974, the journal has become a vital resource for researchers, clinicians, and students alike, covering pioneering studies and cutting-edge advancements in skin health and disease. With a Scopus rank of #32 out of 142 in the Dermatology category, placing it in the 77th percentile, the journal underscores its commitment to fostering knowledge and innovation within the dermatological community. Although the journal operates under a subscription model, it remains an essential platform for disseminating impactful research that shapes clinical practice and enhances patient care. For anyone invested in dermatological sciences, Journal of Dermatology serves as a key publication where critical insights and developments are regularly showcased.